Feldtkeller E,Khan MA,van der Heijde D,et al.Age at disease onset and diagnosis delay in HLA-B27negative vs positive patients with ankylosing spondylitis[J].Rheumatol Int,2003,23:61-66.
[3]
Braun J,Heijde VD.Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides[J].Expert Opin Investing Drugs,2003,12(7):1097-1109.
[4]
唐福林,吴东海.临床诊疗指南-风湿病分册[M].北京:人民卫生出版社,2005:23.
[5]
Higgins JPT,Green S.Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011].The Cochrane Collaboration,2011[OL].Available from:www.Cochrane-handbook.org.
[6]
Braun J,Vander Horst-Bruinsma IE,Huang F,et al.Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis[J].Arthritis & Rheumatism,2011,63(6):1543-1551.
[7]
Song IH,Hermann KG,Haibel H,et al.Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI(ESTHER):a 48-week randomised controlled trial[J].Ann Rheum Dis,2011,70:590-596.
Song IH,Althoff CE,Haibel H,et al.Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis:2 year data of the ESTHER trial[J].Ann Rheum Dis,2013,71(7):1212-1215.
[15]
Braun J,Pavelka K,Ramos-Remus C,et al.Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement[J].The Journal of Rheumatology,2012,39(4):836-840.
[16]
Herman S,Krsnke G,Schett G.Molecular mechanisms of inflammatory bone damage:emerging targets for therapy[J].Trends Mol Med,2008,14(6):245-253.
